Skip to main content

Advertisement

Fig. 5 | Journal of Translational Medicine

Fig. 5

From: HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma

Fig. 5

Negative correlation between HERC5 and CCL20 mRNA and the association of Tregs infiltration in PTs of recurrent patients. a Log2 fold changes HERC5 and CCL20 mRNA between and PNATs in the patients who experienced tumor recurrence (n = 9) or the patients who did not (n = 12). A Student’s paired t-test between HERC5 and CCL20 log2 fold change values for the recurrent patients have p = 0.0003 and p = 0.49 for the non-recurrent patients. Negative correlation between HERC5 and CCL20 mRNA is present in the recurrent patients and not observed in the patients who did not recurrent. b Examples of FOXP3 IHC in PTs and PNATs of a recurrent patient and a non-recurrent patient at ×20 magnification (530 × 460 µm in size per field). c FOXP3 IHC scores were calculated using the average numbers of FOXP3 positive stained lymphocytes in10 randomly selected fields at ×20 magnification (530 × 460 µm in size per field) in hepatocellular carcinoma for each sample. FOXP3 IHC score in PTs of recurrent patients (n = 9) were significantly higher than that in non-recurrent patients (n = 9) by Welch’s modified t-test (p = 0.05)

Back to article page